John Laing Environmental Assets Group (JLEN) has announced the appointment of Hans Joern Rieks as a non-executive director of the company, commencing 13 June 2019.
LXi REIT (LXI), the specialist inflation-protected very long income REIT, has reported annual results for the year ended 31 March 2019. LXI’s leases are typically 20 to 30 years to expiry or first break. The company had a strong year with total returns NAV and total shareholder returns up 12.1% and 30.7%. We note that as of May 13 this year, LXI’s shares were trading at a 16.8% premium to NAV.
Syncona (SYNC) has announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35m commitment in a Series A financing of which Syncona has committed £34.0m with a further £1m being contributed by UCL Technology Fund. Syncona will have a 69.3 per cent stake in the business, with the first tranche of the Series A commitment of £8.3m paid in March 2019. Quell has been established with the aim of developing engineered T regulatory (Treg) cell therapies.
This website is for information purposes only and is not intended to encourage the reader to deal in any mentioned securities. QuotedData is a trading name of Marten & Co Limited, which is authorised and regulated by the Financial Conduct Authority. Some of the content in this website is sponsored and, although it abides by Content Principles and Objectives, (/about-quoteddata/research-principles-objectives/) it is considered non-independent. Investments may involve a significant degree of risk, including loss of capital. The value of an investment and the income from it could go down as well as up. The return of your investment is not guaranteed, and you may get back less than you originally invested. Past performance is not an indicator of future performance. It is important that you read the Terms and Conditions (/about-quoteddata/terms-and-conditions/) before considering any investment.
